WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407344

CAS#: 927822-86-4

Description: KC7F2 is a potent HIF-1 pathway inhibitor with potential anticancer activity. KC7F2 is cytotoxic to a variety of cancer cell lines with an IC50 value of 15-25 µM. KC7F2 markedly inhibited HIF-mediated transcription in cells derived from different tumor types, including glioma, breast, and prostate cancers, and exhibited enhanced cytotoxicity under hypoxia. KC7F2 prevented the activation of HIF-target genes such as carbonic anhydrase IX, matrix metalloproteinase 2 (MMP2), endothelin 1, and enolase 1. KC7F2 worked through the down-regulation of HIF-1alpha protein synthesis, an effect accompanied by the suppression of the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 and p70 S6 kinase, key regulators of HIF-1alpha protein synthesis.

Price and Availability


USD 650
USD 3250

USD 1050
USD 4850

USD 1950
USD 6850

KC7F2, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 407344
Name: KC7F2
CAS#: 927822-86-4
Chemical Formula: C16H16Cl4N2O4S4
Exact Mass: 567.8747
Molecular Weight: 570.354
Elemental Analysis: C, 33.69; H, 2.83; Cl, 24.86; N, 4.91; O, 11.22; S, 22.48

Synonym: KC7F2

IUPAC/Chemical Name: N,N'-(disulfanediylbis(ethane-2,1-diyl))bis(2,5-dichlorobenzenesulfonamide)


InChi Code: InChI=1S/C16H16Cl4N2O4S4/c17-11-1-3-13(19)15(9-11)29(23,24)21-5-7-27-28-8-6-22-30(25,26)16-10-12(18)2-4-14(16)20/h1-4,9-10,21-22H,5-8H2

SMILES Code: ClC1=C(S(NCCSSCCNS(C2=C(Cl)C=CC(Cl)=C2)(=O)=O)(=O)=O)C=C(Cl)C=C1

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Huang X, He Z, Jiang X, Hou M, Tang Z, Zhen X, Liang Y, Ma J. Folic Acid Represses Hypoxia-Induced Inflammation in THP-1 Cells through Inhibition of the PI3K/Akt/HIF-1α Pathway. PLoS One. 2016 Mar 14;11(3):e0151553. doi: 10.1371/journal.pone.0151553. eCollection 2016. PubMed PMID: 26974319; PubMed Central PMCID: PMC4790958.

2: Cheng CC, Guan SS, Yang HJ, Chang CC, Luo TY, Chang J, Ho AS. Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer. J Biomed Sci. 2016 Jan 28;23:18. doi: 10.1186/s12929-016-0219-6. PubMed PMID: 26822586; PubMed Central PMCID: PMC4730655.

3: Guan G, Zhang Y, Lu Y, Liu L, Shi D, Wen Y, Yang L, Ma Q, Liu T, Zhu X, Qiu X, Zhou Y. The HIF-1α/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells. Cancer Lett. 2015 Feb 1;357(1):254-64. doi: 10.1016/j.canlet.2014.11.034. Epub 2014 Nov 18. PubMed PMID: 25444927.

4: Li J, Jiang G, Chen Y, Chen L, Li Z, Wang Z, Wang X. Altered expression of hypoxia-Inducible factor-1α participates in the epileptogenesis in animal models. Synapse. 2014 Sep;68(9):402-9. doi: 10.1002/syn.21752. Epub 2014 Jun 17. PubMed PMID: 24889205.

5: Rathnasamy G, Ling EA, Kaur C. Hypoxia inducible factor-1α mediates iron uptake which induces inflammatory response in amoeboid microglial cells in developing periventricular white matter through MAP kinase pathway. Neuropharmacology. 2014 Feb;77:428-40. doi: 10.1016/j.neuropharm.2013.10.024. Epub 2013 Nov 1. PubMed PMID: 24184387.

6: Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC, Van Meir EG. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res. 2009 Oct 1;15(19):6128-36. doi: 10.1158/1078-0432.CCR-08-3180. Epub 2009 Sep 29. PubMed PMID: 19789328; PubMed Central PMCID: PMC2770235.

7: Koh MY, Spivak-Kroizman TR, Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin Cancer Res. 2009 Oct 1;15(19):5945-6. doi: 10.1158/1078-0432.CCR-09-1650. Epub 2009 Sep 29. PubMed PMID: 19789327; PubMed Central PMCID: PMC2760048.